These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21801213)

  • 1. Do pentoxifylline and ascorbic acid improve erythropoiesis stimulating agent resistance?
    Rho M
    Semin Dial; 2011; 24(4):378-9. PubMed ID: 21801213
    [No Abstract]   [Full Text] [Related]  

  • 2. Choice of erythropoiesis stimulating agent in ESRD.
    Fishbane S; Shah HH
    Nephrol News Issues; 2013 Jun; 27(7):Supp 10-2. PubMed ID: 23855143
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 4. Peginesatide: a potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
    Doss S; Schiller B
    Nephrol Nurs J; 2010; 37(6):617-26. PubMed ID: 21290916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
    Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
    Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations.
    Dutka P
    Nephrol Nurs J; 2012; 39(6):447-57. PubMed ID: 23469411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ascorbic acid use in hyporesponders to Epoetin alfa.
    Gibbs MA
    Nephrol Nurs J; 2000 Aug; 27(4):413-5. PubMed ID: 11276634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS).
    Veys N; Van Biesen W; Lameire N
    Acta Clin Belg; 2007; 62(6):396-407. PubMed ID: 18351184
    [No Abstract]   [Full Text] [Related]  

  • 9. [Erythropoesis-stimulating agents: 21 years of clinical experience].
    Kes P
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():1-2. PubMed ID: 20235350
    [No Abstract]   [Full Text] [Related]  

  • 10. [Role of renal anemia in progression of chronic kidney disease].
    Racki S; Maleta I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CERA: third-generation erythropoiesis-stimulating agent.
    Topf JM
    Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference.
    Easom A
    Nephrol Nurs J; 2009; 36(5):529-37, 553. PubMed ID: 19856814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia and cardiovascular risk in the patient with kidney disease.
    Fishbane S
    Heart Fail Clin; 2008 Oct; 4(4):401-10. PubMed ID: 18760752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginesatide (Omontys) for anemia in chronic kidney failure.
    Med Lett Drugs Ther; 2012 Jun; 54(1392):45-6. PubMed ID: 22683926
    [No Abstract]   [Full Text] [Related]  

  • 15. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?].
    Kessler M; Salignac S; Aimone-Gastin I
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: Adjuvant therapies to reduce erythropoiesis-stimulating agent dose requirements.
    Shah HH; Fishbane SN
    Semin Dial; 2013; 26(5):543-5. PubMed ID: 23763709
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoietin, an update, and where to in the future?
    Sulková S
    EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
    Gupta G; Choi MJ
    Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.